

# Tumor Somatic Immune Phenotype Prediction Driven by DNA Sequence and Deep Learning

Tianrui Qi, Jing He

Oncology Group  
Therapeutic Area Genetics (TAG)  
Regeneron Genetics Center (RGC)

# Background

## Significance:

- **What?** Describe the presence and activity of immune cells such as T cells and macrophages within the tumor tissue, i.e., immune response.
- **How?** Assessed using techniques like immunohistochemistry, flow cytometry, and genomic sequencing methods such as RNA sequencing to quantify immune cells in the tumor.
- **Why?** Predict a patient's response to immunotherapy; higher infiltration indicating increased sensitivity to treatment, i.e., may achieve better outcomes.

## Opportunity 1: Data

- Stanford data (#patients = 8, #samples = 23, normal and tumor):  
Basal Cell Carcinoma pre and post anti-PD1 treatment that enhanced tumor immune infiltration.
- TCGA SKCM data (#patients = 470, #samples = 928, normal blood and tumor):  
Leukocyte Fraction from other omics data.
- RGC data (Germline WXS from blood)

## Opportunity 2: Method

- [DNABERT](#) (2021): State-of-art performance on prediction of promoters, splice sites and transcription factor binding sites (human).
- [DNABERT2](#) (2023): State-of-art performance across 28 distinct datasets across 7 tasks and 4 species (human, mouse, yeast, virus).


| Species | Task                            | Num. Datasets | Num. Classes | Sequence Length |
|---------|---------------------------------|---------------|--------------|-----------------|
| Human   | Core Promoter Detection         | 3             | 2            | 70              |
|         | Transcription Factor Prediction | 5             | 2            | 100             |
|         | Promoter Detection              | 3             | 2            | 300             |
|         | Splice Site Detection           | 1             | 3            | 400             |
| Mouse   | Transcription Factor Prediction | 5             | 2            | 100             |
| Yeast   | Epigenetic Marks Prediction     | 10            | 2            | 500             |
| Virus   | Covid Variant Classification    | 1             | 9            | 1000            |

Table 1: Summarization of the Genome Understanding Evaluation (GUE) benchmark.

# Background: More About Model

## BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding

Jacob Devlin Ming-Wei Chang Kenton Lee Kristina Toutanova  
Google AI Language  
{jacobdevlin, mingweichang, kentonl, kristout}@google.com




Genome analysis

## DNABERT: pre-trained Bidirectional Encoder Representations from Transformers model for DNA-language in genome

Yanrong Ji<sup>1,†</sup>, Zhihan Zhou<sup>2,†</sup>, Han Liu<sup>2,\*</sup> and Ramana V. Davuluri<sup>3,\*</sup>

<sup>1</sup>Division of Health and Biomedical Informatics, Department of Preventive Medicine, Northwestern University Feinberg School of



## DNABERT-2: EFFICIENT FOUNDATION MODEL AND BENCHMARK FOR MULTI-SPECIES GENOME

Zhihan Zhou\* Yanrong Ji\* Weijian Li\* Pratik Dutta† Ramana Davuluri† Han Liu\*  
Northwestern University\* Stony Brook University†

| Iteration | Corpus            | Vocabulary      |
|-----------|-------------------|-----------------|
| 0         | AACGCACTATATA     | {A,T,C,G}       |
| 1         | AACGCACTATATA     | {A,T,C,G,TA}    |
| 2         | AACGCACTATA TA TA | {A,T,C,G,TA,AC} |
| 3         | AACGCACTATA TA TA | .....           |

**Non-Overlapped**

|            |                  |
|------------|------------------|
| Sequence 1 | ACAATAATAATAACGG |
| Sequence 2 | CAATAATAATAACGG  |

**Tokens**

|        |        |        |   |                       |
|--------|--------|--------|---|-----------------------|
| ACAATA | ATAATA | ATAACG | G | [520, 264, 271, 4103] |
| CAATAA | TAATAA | TAACGG |   | [2068, 1044, 1075]    |

**Ours**


|     |              |              |     |                   |
|-----|--------------|--------------|-----|-------------------|
| A   | CAA          | TAATAATAATAA | CGG | [5, 27, 1769, 72] |
| CAA | TAATAATAATAA | CGG          |     | [27, 1769, 72]    |

- Encoder-only models that utilize global context instead of decoder-only models like GPT that are unidirectionally.
- Useful when final predictions have high accuracy based off only an embedding / representation of the inputted sequence

- k-merization scheme for tokenizing the genome to extend BERT from human language to DNA sequence

- Improve the tokenizing by compression algorithm Byte Pair Encoding (BPE) that merges frequent pairs of nucleotides instead a specific k-mer
- Biologically significant tokens


# Goals



- Goal 1: Viability of predict tumor immune infiltration by DNA sequence on Stanford data
- Goal 2: Finetune the pipeline on TCGA SKCM data
- Goal 3: Predict on RGC data

# Challenges: Requiring Context-specific Adaptation

## Problem DNABERT2 Tries to Solve



| Species | Task                            | Num. Datasets | Num. Classes | Sequence Length |
|---------|---------------------------------|---------------|--------------|-----------------|
| Human   | Core Promoter Detection         | 3             | 2            | 70              |
|         | Transcription Factor Prediction | 5             | 2            | 100             |
|         | Promoter Detection              | 3             | 2            | 300             |
|         | Splice Site Detection           | 1             | 3            | 400             |
| Mouse   | Transcription Factor Prediction | 5             | 2            | 100             |
| Yeast   | Epigenetic Marks Prediction     | 10            | 2            | 500             |
| Virus   | Covid Variant Classification    | 1             | 9            | 1000            |


Table 1: Summarization of the Genome Understanding Evaluation (GUE) benchmark.

DNABERT2

## Problem We Try to Solve

- Gap between sequence and sample level prediction:
1. Number of reads vary by samples, chromosomes
  2. Reads between samples not match, cannot compare directly


- How we going to solve:
1. Feature select the most informative positions
  2. Extract reads from these positions to represent the sample



SIP-DB2 somatic immune phenotype prediction based on DNABERT2


# ● Methods(v1): How to Represent a Given WXS Sample?

## Problem We Try to Solve




## Select Features

c: index of chromosome, 1-22 & X  
 $N_c$ : num of reads for chromosome c, all samples  
 $K_c$ : num of features(positions) for chromosome c, i.e.,  $K_c = 0.1 \times N_c$




# ● Methods(v1): How to Represent a Given WXS Sample?

## Problem We Try to Solve




## Represent Sample Using Selected Features



# Methods(v1): Profiling of Each Steps

## Problem We Try to Solve



### Filter Sequence using SNPs

#### Resource

- CPU: 1 core / process
- Memory: 45GB / process; depend on length (bp) of WXS, which is fixed
- Disk: 0.2GB / 1M reads; 30GB / sample with 150M reads

#### Speed

- 30K reads / second; 1.5 hour / sample with 150M reads

### Sequence to Embedding

#### Resource

- CPU: 1 core / process
- GPU (T4): at least 2GB / process; depend on batch size
- Memory: 3GB / 1M reads; depend on number of reads and save to disk frequency
- Disk: 3GB / 1M reads; 4.5GB / sample with 1.5M reads after SNPs filter

#### Speed

- 500 reads / second; 1 hour / sample with 1.5M reads after SNPs filter

### Feature Selection

#### Resource

- CPU: 5 core / process
- Memory: 2GB / sample pair where each sample with 1.5M reads after SNPs filter
- Disk: 0.5MB / 1M reads; 300MB if we use 400 samples with 1.5M reads each


#### Speed

- 1 second / sample pair with 1.5M reads each after SNPs filter; O(sample<sup>2</sup>)



# Results: Biological Interpretation of the Top Features


Distribution of features' distance of chromosome 6  
Feature Selection by method(v1)  
Train on Stanford (N=23)



Distance can use as score to indicate how important this feature/position is







| Chr | Position         | Annotation                                                                                                                                                                                    |
|-----|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 6   | 31148372         | HLA-C                                                                                                                                                                                         |
| 6   | <b>150064576</b> | ULBP3: NKG2D ligand, ULBP3 are expressed on immature and mature dendritic cells and plays an important role in the cytotoxic effect of NK cells against iDC.                                  |
| 6   | 31271878         | HLA-C                                                                                                                                                                                         |
| 6   | <b>90147296</b>  | BACH2: Enables sequence-specific double-stranded DNA binding activity. Involved in primary adaptive immune response involving T cells and B cells.                                            |
| 6   | 31271900         | HLA-C                                                                                                                                                                                         |
| 6   | 31222832         | nearest gene HCG27 and HLA-C. LncRNA HCG27 Promotes Glucose Uptake Ability of HUVECs by MiR-378a-3p/MAPK1 Pathway                                                                             |
| 6   | 31586832         | LST1, leukocyte specific transcript 1                                                                                                                                                         |
| 6   | 150025312        | RAET1L, RAET1L belongs to the RAET1 family of major histocompatibility complex (MHC) class I-related genes, which are located within a 180-kb cluster on chromosome 6q24.2-q25.3.             |
| 6   | 31271884         | HLA-C                                                                                                                                                                                         |
| 6   | 32052816         | TNXB, tenascin XB, his protein plays an important role in organizing and maintaining the structure of tissues that support the body's muscles, joints, organs, and skin (connective tissues). |

# Results: Biological Interpretation of the Top Features



# Results: Anti-PD1 Treated Basal Cell Carcinoma Patients from Stanford



- Features select from 23 chromosome of all Stanford data
- Projection of embedding to PCA
- Visualization of metadata on PCA (unsupervised)



# Results: Anti-PD1 Treated Basal Cell Carcinoma Patients from Stanford

- Features select from 23 chromosome of all Stanford data samples
- Projection of embedding to PCA
- Visualization of metadata on PCA (unsupervised)

Color by Treatment



# Results: Anti-PD1 Treated Basal Cell Carcinoma Patients from Stanford

## Supplemental for Stanford Metadata

| Patient | Tumor Type | Treatment     | Ongoing Vismodegib treatment | Prior treatment | Response | Best % change | pre site | days pre treatment | post site | scRNA days post treatment | Adaptive pre site | Adaptive days pre treatment | Adaptive post site | Adaptive days post treatment | PBMC Adaptive days pre treatment | PBMC Adaptive days post treatment | Exome pre site | Exome days pre treatment | Exome post site | Exome days post treatment |
|---------|------------|---------------|------------------------------|-----------------|----------|---------------|----------|--------------------|-----------|---------------------------|-------------------|-----------------------------|--------------------|------------------------------|----------------------------------|-----------------------------------|----------------|--------------------------|-----------------|---------------------------|
| su001   | BCC        | Pembrolizumab | +                            | Vismodegib      | Yes      | -81           | L arm    | -239, -78          | L arm     | 83                        | L arm             | -78, -5                     | L arm              | 83, 146                      | -239                             | 104                               | L arm          | -78                      | L arm           | 146                       |
| su002   | BCC        | Pembrolizumab | -                            | Vismodegib      | Yes      | 0*            | Nose     | 0                  | Nose      | 62                        | Nose              | -602                        | NA                 | NA                           | NA                               | 117                               | Nose           | 0                        | Nose            | 62                        |
| su003   | BCC        | Pembrolizumab | -                            | Vismodegib      | Yes      | -100          | R arm    | -243               | R chest   | 16, 121                   | NA                | NA                          | R chest            | 15                           | -243                             | 16                                | R arm          | -244                     | R arm           | 155                       |
| su004   | BCC        | Cemiplimab    | -                            | -               | Yes      | -25           | Knee     | 1                  | Knee      | 38                        | NA                | NA                          | NA                 | NA                           | NA                               | NA                                | Knee           | 0                        | NA              | NA                        |
| su005   | BCC        | Pembrolizumab | -                            | Vismodegib      | No       | 5             | L ear    | 0                  | L ear     | 105                       | L ear             | -28                         | L ear              | 42                           | 0                                | 42                                | L ear          | 0                        | L ear           | 105                       |
| su006   | BCC        | Pembrolizumab | +                            | Vismodegib      | No       | -11           | R neck   | 0                  | R neck    | 21                        | R neck            | -280                        | R neck             | 140                          | -84                              | 140                               | R neck         | -79                      | R neck          | 21                        |
| su007   | BCC        | Pembrolizumab | -                            | Vismodegib      | No       | 10            | L cheek  | -3                 | L cheek   | 60                        | L cheek           | -3                          | L cheek            | 60                           | -1855                            | 39                                | L cheek        | -3                       | L cheek         | 60                        |
| su008   | BCC        | Pembrolizumab | +                            | Vismodegib      | No       | 0             | R arm    | -91                | R arm     | 43                        | R arm             | -43                         | R arm              | 42                           | -98                              | 43                                | NA             | NA                       | R arm           | 43                        |

# Results: Immune Prediction of Untreated Melanoma Patient from TCGA


- Features select from 23 chromosome of all Stanford data samples
- Projection of embedding to PCA
- Visualization of metadata on PCA (unsupervised)
- 13/17 samples predicted correctly

Ground Truth of Leukocyte Fraction




Prediction of Leukocyte Fraction

|       | < 0.5 | > 0.5 |
|-------|-------|-------|
| < 0.5 | 6     | 3     |
| > 0.5 | 1     | 7     |

Color by Patient





Color by Leukocyte Fraction



# Results: Immune Prediction of Untreated Melanoma Patient from TCGA

- Features select from 23 chromosome of all Stanford data samples
- Projection of embedding to PCA
- Visualization of metadata on PCA (unsupervised)
- 13/17 samples predicted correctly



# Results: Immune Prediction of Untreated Melanoma Patient from TCGA


## Supplemental for TCGA Metadata

| TCGA Participant Barcode | TCGA Subtype         | DL prediction | DL predict correct | Leukocyte Fraction | Th1 Cells | Th2 Cells | T Cells CD8 | Eosinophils |
|--------------------------|----------------------|---------------|--------------------|--------------------|-----------|-----------|-------------|-------------|
| TCGA-EE-A2GK             | SKCM.Triple_WT       | Low           | No                 | 0.90               | -769.06   | -647.24   | 0.08        | 0.00        |
| TCGA-EB-A5VV             | NA                   | High          | Yes                | 0.90               | -667.82   | -1124.27  | 0.12        | 0.00        |
| TCGA-EE-A2ME             | SKCM.BRAF_Hotspot_Mi | High          | No                 | 0.80               | 368.91    | 896.15    | 0.28        | 0.00        |
| TCGA-FR-A7UA             | NA                   | High          | Yes                | 0.78               | 1236.60   | 279.26    | 0.41        | 0.00        |
| TCGA-FW-A5DY             | NA                   | High          | Yes                | 0.76               | -79.90    | -633.45   | 0.10        | 0.00        |
| TCGA-EE-A3JD             | SKCM.NF1_Any_Mutants | High          | Yes                | 0.72               | 798.37    | 763.81    | 0.16        | 0.00        |
| TCGA-D3-A8GP             | NA                   | High          | No                 | 0.05               | -1108.04  | 233.51    | 0.27        | 0.00        |
| TCGA-D9-A6EC             | NA                   | Low           | Yes                | 0.04               | -176.10   | 336.34    | 0.04        | 0.00        |
| TCGA-EE-A3AD             | SKCM.BRAF_Hotspot_Mi | Low           | Yes                | 0.04               | -567.50   | 735.12    | 0.00        | 0.00        |
| TCGA-EE-A3AH             | SKCM.BRAF_Hotspot_Mi | Low           | Yes                | 0.04               | -1060.93  | 389.18    | 0.08        | 0.01        |
| TCGA-D3-A3ML             | SKCM.RAS_Hotspot_Mut | High          | No                 | 0.03               | -71.67    | 677.88    | 0.20        | 0.00        |
| TCGA-FS-A1ZY             | SKCM.RAS_Hotspot_Mut | High          | No                 | 0.02               | -1010.42  | 402.17    | 0.13        | 0.00        |




# Results: Immune Prediction of Untreated Melanoma Patient from TCGA

- Features select from 23 chromosome of all Stanford data samples
- Projection of embedding to PCA
- Visualization of metadata on PCA (unsupervised)
- 13/17 samples predicted correctly




# Challenges: Scaling Up from Stanford (N=23) to TCGA (N=928)

## Problem We Try to Solve




## Select Features

c: index of chromosome, 1-22 & X  
 $N_c$ : num of reads for chromosome c, all samples  
 $K_c$ : num of features(positions) for chromosome c, i.e.,  $K_c = 0.1 \times N_c$




# ● Methods(v2): Bucket Version of Selecting Features

## Problem We Try to Solve




## Select Features





# ● Methods(v2): How Bucket Version Address the Challenges?

## Problem We Try to Solve



## Linear Computing Time




identify key buckets within genes of the same function but vary across samples

identify key buckets that are most dissimilar gene across regions


Only calculate distance within buckets still capture information we need

# ● Methods(v2): How Bucket Version Address the Challenges?


## Problem We Try to Solve




## Linear Computing Time



## Parallel Computing



## Next Steps




- Goal 1: Viability of predict tumor immune infiltration by DNA sequence on Stanford data
- Goal 2: Finetune the pipeline on TCGA SKCM data
- Goal 3: Predict on RGC data


### Verify Our Assumption

Differences of positions/buckets between

- v1 and v2 features
- Stanford and TCGA features by
- checking covered regions
- cross validating the pipeline before jump to prediction



## Next Steps




- Goal 1: Viability of predict tumor immune infiltration by DNA sequence on Stanford data
- Goal 2: Finetune the pipeline on TCGA SKCM data
- Goal 3: Predict on RGC data

### Verify Our Assumption

Differences of positions/buckets between

- v1 and v2 features
- Stanford and TCGA features by
- checking covered regions
- cross validating the pipeline before jump to prediction


### Method



By vectorizing WXS samples:

- reduce computational demand
- efficient similarity searches
- scalability and multimodality





- Exposed me to data volumes far surpassing those in prior research, sharpening my skills in algorithm design, engineering, and optimization.
- It instilled a translational mindset, an awareness of scalability and practical application, that I aim to bring into optical imaging.

